Vaccitech: Margaret Marshall, Georgy Egorov, Simon Alvis
Vaccitech (a spin-out company from the University of Oxford's Jenner Institute; and which co-invented the AstraZeneca / Oxford COVID-19 vaccine candidate AZD1222) has made three senior appointments.
Margaret (Meg) Marshall, M.D. becomes Vaccitech's full-time Chief Medical Officer, having worked as a consultant for the company since June. Dr. Marshall has over 25 years of experience in the preclinical and clinical development of cell and antibody-based immunotherapy for infectious disease and cancer. Prior to joining Vaccitech, she held directorship positions in the clinical research departments of Kyowa Kirin, Kite Pharma and Pfizer.
Georgy Egorov joins Vaccitech as Chief Financial Officer. Egorov brings more than 20 years of senior finance, strategy, investment banking and capital markets experience as well as extensive knowledge of investor relations and corporate development to the company. Egorov joins Vaccitech from Exscientia, a global leader in AI drug discovery; and has previously worked at Goldman Sachs and UBS.
Simon Alvis, Ph.D., joins Vaccitech as Vice President Manufacturing. Since 1999, Dr. Alvis has cultivated a broad expertise across process, analytical and formulation development of viral and recombinant protein biological drug products. He joins Vaccitech after leading viral manufacturing programs at PsiOxus Therapeutics.
Vaccitech develops T cell vaccines and immunotherapies designed to treat and prevent infectious disease and cancer.